Home > HP (current issue) > Special features | Search

PJ Online homeHospital Pharmacist
2008;15:119-124
April 2008

Hospital Pharmacist back issues

Special features

Valvular heart disease — pathophysiology and management

By Sukhjinder Nijjer, MB ChB, MRCP, Jasdeep Gill, MB ChB, and Sandeep Nijjer, MPharm, MRPharmS

The valves of the heart can be affected by a number of diseases and drugs. This article describes the most common types of valvular heart disease, the symptoms and diagnosis, and how the disease is managed with drugs and surgical intervention

FULL TEXT article PDF (90K)


Diagnosing valvular heart disease

Sukhjinder Nijjer is specialty registrar, cardiology, at the Royal Brompton Hospital, London

Jasdeep Gill is a foundation doctor, general medicine, at Southampton General Hospital

Sandeep Nijjer is a clinical lecturer at the University of London School of Pharmacy

CNRI/SPL

Prosthetic heart valve

A prosthetic heart valve (“caged ball” type) replacing the mitral valve

SUMMARY

Valvular heart disease (VHD) is common and it is essential that hospital pharmacists understand the disease and the role of pharmacotherapy in its treatment and prevention.

The heart is composed of four chambers (two atria and two ventricles) and contains four valves (mitral and aortic valves on the left, tricuspid and pulmonary valves on the right).

The valves prevent blood flowing backwards within the systemic (left side) and pulmonary (right side) circulations.

Many disease processes affect the cardiac valves. Disease may cause valve stenosis (narrowing) or regurgitation (blood leaking in the wrong direction), with haemodynamic consequences.

Acute or subacute infection, most commonly bacterial endocarditis, can destroy heart valves, as can connective tissue diseases. Diseases of the chambers can also affect the valves and cause functional disease.

Thirty years ago, the most common cause of VHD in people under the age of 60 years was rheumatic heart disease — an immunological reaction to streptococcal infection. Widespread antibiotic use has reduced the incidence of rheumatic heart disease, and the most common form of VHD is now degenerative valvular disease in elderly patients.

Comorbidity is common; atherosclerosis, renal impairment and chronic obstructive pulmonary disease are the most frequent conditions found in VHD patients.

Increasing numbers of patients are now undergoing valve replacement operations, and optimising cardiac function in patients awaiting these operations has become an important aspect of patient care. Following surgery, there is a strong emphasis on anti-coagulation monitoring and antibiotic prophylaxis against endocarditis.

This article will describe how the six most common forms of VHD are managed. A second article (p127) focuses on anticoagulation and prophylaxis of endocarditis.

Diagnosing valvular heart disease

Patients with VHD can present with a variety of symptoms. These typically include breathlessness, lethargy, chest pain or collapse.

Echocardiography is the investigation of choice, producing two-dimensional images of cardiac anatomy and dysfunctional valves. However, echocardiography is performer dependent and serial studies are required to aid decision making. Magnetic resonance imaging can complement echocardiographic data.

Colour Doppler and Doppler studies are used to assess the haemodynamic consequences of the disease (eg, the valve area, the velocity of flow across a valve and the effective regurgitant orifice area). Some specialist centres also use computerised topography to assess valvular calcification and exclude concomitant coronary artery disease.

Back to Top


©The Pharmaceutical Journal